Press Releases

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study to combine therapies in patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) EAGAN, MN — February 23, 2017 — Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with...

Read More


Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017

EAGAN, MN — February 15, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual Molecular Medicine Tri-Conference, taking place at the Moscone North Convention Center, San Francisco, February 19-24, 2017. Jeremy R. Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera Pharmaceuticals, will present data showing that...

Read More


Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Trial to Test Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab) EAGAN, MN — December 5, 2016 — Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and Canada) to include a Phase 2 clinical study investigating Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in second- and third-line patients...

Read More


Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Researchers to Present Preclinical Data at EORTC-NCI-AACR Symposium EAGAN, MN — November 29, 2016 — Biothera Pharmaceuticals, Inc. will present data tomorrow illustrating the unique cytokine response generated by its phase 2 cancer immunotherapy Imprime PGG, the only Pathogen Associated Molecular Patterning (PAMP) molecule that has been successfully administered systemically. The data will be highlighted in two poster presentations at the 28th EORTC-NCI-AACR Symposium on Molecular...

Read More


Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG

3 Poster Presentations Scheduled for Society for Immunotherapy of Cancer Annual Meeting EAGAN, MN — November 11, 2016 — Biothera Pharmaceuticals, Inc. will present new preclinical data today that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies. The data will be highlighted in three...

Read More


Preclinical Data Published in PLOS ONE Support Use of a Patient Selection Biomarker for Biothera Pharmaceuticals’ Phase 2 Cancer Immunotherapy Imprime PGG

Formation of Imprime PGG-Immune Complex Essential to Anti-Tumor Activity EAGAN, MN — November 7, 2016 — Biothera Pharmaceuticals, Inc. today announced the publication of preclinical research identifying an essential mechanism in the activation of anti-cancer immune responses by Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug. The formation of an immune complex between Imprime PGG and endogenous anti-beta glucan antibodies (ABA) offers the potential...

Read More


Clinical Data Support Mechanism of Action and Patient Selection Biomarker for Imprime PGG, Biothera Pharmaceutical’s Phase 2 Cancer Immunotherapy

Clinical findings presented at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference EAGAN, MN — September 27, 2016 — Biothera Pharmaceuticals, Inc. today announced the presentation of clinical data demonstrating the mechanism of action of Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug, in healthy human volunteers. These are the first data to show that when administered intravenously to healthy human subjects, Imprime PGG drives the immunopharmacodynamic...

Read More


Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC) EAGAN, MN — August 24, 2016 — Biothera Pharmaceuticals, Inc. today announced...

Read More


Biothera Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

EAGAN, MN — August 3, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:30 a.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera Pharmaceuticals and a business update. About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company...

Read More


Biothera Pharmaceuticals to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum

EAGAN, MN — May 31, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum on Friday, June 3, 2016 at 2:30 p.m. Central Time in Chicago. Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase...

Read More



Page 1 of 612345...Last »